Kyung Dong Pharmaceutical Co., Ltd.

KOSDAQ:A011040 Stock Report

Market Cap: ₩158.1b

Kyung Dong Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Kyung Dong Pharmaceutical's earnings have been declining at an average annual rate of -49.1%, while the Pharmaceuticals industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 0.6% per year. Kyung Dong Pharmaceutical's return on equity is 2.5%, and it has net margins of 2.8%.

Key information

-49.10%

Earnings growth rate

-50.93%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate0.58%
Return on equity2.47%
Net Margin2.82%
Last Earnings Update31 Dec 2024

Recent past performance updates

Kyung Dong Pharmaceutical (KOSDAQ:011040) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 30
Kyung Dong Pharmaceutical (KOSDAQ:011040) Is Posting Healthy Earnings, But It Is Not All Good News

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 19
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

Kyung Dong Pharmaceutical (KOSDAQ:011040) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 30
Kyung Dong Pharmaceutical (KOSDAQ:011040) Is Posting Healthy Earnings, But It Is Not All Good News

Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Mar 07
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?

Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Feb 18
Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Feb 03
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?

Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Jan 19
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?

Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

Jan 04
Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals

How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

Dec 20
How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?

We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Dec 05
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease

Revenue & Expenses Breakdown

How Kyung Dong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A011040 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24193,9365,47098,62111,120
30 Sep 24189,188-17,00595,86014,680
30 Jun 24178,594-16,53491,94014,841
31 Mar 24170,232-18,92088,36514,704
31 Dec 23162,674-20,70886,47113,827
30 Sep 23165,7096,82481,02413,189
30 Jun 23174,1438,71076,38513,287
31 Mar 23173,1098,42274,42311,951
31 Dec 22182,71812,16170,60212,618
30 Sep 22181,7986,50671,89712,469
30 Jun 22183,6839,17971,61012,137
31 Mar 22185,79312,29170,19811,813
31 Dec 21177,61112,67268,44410,537
30 Sep 21175,89413,57768,55710,877
30 Jun 21172,33211,66968,38010,146
31 Mar 21171,85311,08767,6949,767
31 Dec 20173,82812,45966,54010,063
30 Sep 20175,09112,91666,1309,818
30 Jun 20174,26318,54966,5069,490
31 Mar 20176,34820,78866,5379,589
31 Dec 19176,50020,12667,7378,918
30 Sep 19175,9065,75166,8918,262
30 Jun 19177,8423,15565,9157,142
31 Mar 19175,6023,19365,3796,274
31 Dec 18179,3165,24264,5515,869
30 Sep 18180,11216,91264,7455,510
30 Jun 18181,52818,70065,1655,626
31 Mar 18181,86120,56264,5135,778
31 Dec 17177,77220,47764,2655,648
30 Sep 17173,02222,22262,8765,667
30 Jun 17166,64019,44461,8805,735
31 Mar 17162,70318,67061,7945,336
31 Dec 16158,59917,60961,2265,033
30 Sep 16155,70518,62960,4115,090
30 Jun 16153,07913,67363,4105,061
31 Mar 16150,79313,92860,4365,956
31 Dec 15151,89314,13260,5245,156
30 Sep 15153,19515,39555,7937,783
30 Jun 15151,28822,40450,0236,758
31 Mar 15153,28622,92450,1534,747
31 Dec 14153,26024,51848,2534,771
30 Sep 14151,58123,89148,5204,226
30 Jun 14148,23625,78747,8534,229

Quality Earnings: A011040 has a large one-off gain of ₩1.7B impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: A011040 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A011040's earnings have declined by 49.1% per year over the past 5 years.

Accelerating Growth: A011040 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A011040 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.06%).

Return on Equity

High ROE: A011040's Return on Equity (2.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 09:18
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyung Dong Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hong-Sik JeongLS Securities Co., Ltd.
Tae Gi HaSK Securities Co., Ltd.